C07C 311/23
Having the sulfur atoms of the sulfonamide groups bound to acyclic carbon
Official title: having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
C07C311/23 (Having the sulfur atoms of the sulfonamide groups bound to acyclic carbon) appears on 103 US grants and 87 published applications in this corpus.
Search patents in C07C- Granted patents
- 103
- Published applications
- 87
- Assignees
- 74
- Inventors
- 335
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 5 | 0 |
| 1998 | 7 | 0 |
| 1999 | 7 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 0 |
| 2002 | 7 | 5 |
| 2003 | 8 | 4 |
| 2004 | 1 | 9 |
| 2005 | 3 | 7 |
| 2006 | 5 | 8 |
| 2007 | 6 | 5 |
| 2008 | 6 | 3 |
| 2009 | 2 | 3 |
| 2010 | 3 | 2 |
| 2011 | 1 | 6 |
| 2012 | 2 | 2 |
| 2013 | 1 | 1 |
| 2014 | 1 | 5 |
| 2015 | 4 | 3 |
| 2016 | 2 | 2 |
| 2017 | 1 | 2 |
| 2018 | 2 | 1 |
| 2019 | 3 | 3 |
| 2020 | 2 | 2 |
| 2021 | 2 | 2 |
| 2022 | 1 | 2 |
| 2023 | 1 | 3 |
| 2024 | 1 | 4 |
| 2025 | 2 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Inhibitors of the Wnt/beta-catenin pathway2 Sep 2025US 12,404,243 B2The Regents of the University of California
- Ion channel antagonists/blockers and uses thereof7 Jan 2025US 12,187,681 B2Shanghai East Hospital
- Aryl alkynamide derivatives27 Feb 2024US 11,912,679 B2Astellas Pharma Inc.
- Inhibitors of the WNT/beta-catenin pathway25 Jul 2023US 11,708,329 B2The Regents of the University of California
- Ultra short acting anti-arrhythmic agents29 Mar 2022US 11,286,235 B2Academic Pharmaceuticals, Inc.
- Kif18a inhibitor compound, and pharmaceutical composition and preparation method therefor and use thereof1 Oct 2026US 2026/0294927 A1Changchun Genescience Pharmaceutical Co., Ltd.
- Aryl alkynamide derivatives5 Jun 2025US 2025/0177349 A1Astellas Engineered Small Molecules US, Incorporated
- Modulators of the integrated stress pathway17 Apr 2025US 2025/0122188 A1AbbVie Inc.
- Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents11 Jul 2024US 2024/0226026 A1ModernaTX, Inc.
- Cationic lipid6 Jun 2024US 2024/0180954 A1Shionogi & Co., Ltd.
Most cited
By later US patents
- Methods and compositions for inhibiting cell proliferative disorders109US 5,789,427 ASugen, Inc. · 1998
- Methods and compositions for inhibiting cell proliferative disorders85US 5,773,476 ASugen, Inc. · 1998
- α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors56US 6,248,775 B1G. D. Searle & Co. · 2001
- .alpha.-and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors43US 5,843,946 AG. D. Searle & Co. · 1998
- .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors42US 6,060,476 AG. D. Searle & Co. · 2000